Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?

被引：0
|
作者：
Cerrato, Clara [1 ]
Roupret, Morgan [2 ]
Mir, Maria Carmen [3 ,4 ]
机构：
[1] Univ Verona, Azienda Osped Univ Integrata, Dept Urol, Verona, Italy
[2] Sorbonne Univ, Pitie Salpetriere Hosp, Dept Urol, GRC Predict Oncouro 5, Paris, France
[3] Alzira Univ Hosp, Dept Urol, Valencia, Spain
[4] Alzira La Ribera Univ Hosp, Dept Urol, Valencia, Spain
来源：
EUROPEAN UROLOGY | 2023年 / 83卷 / 06期
关键词：
D O I：
10.1016/j.eururo.2023.03.004
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：505 / 507
页数：3
相关论文
共 50 条
  • [1] Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial
    Angulo, Javier C.
    Alvarez-Ossorio, Jose L.
    Dominguez-Escrig, Jose L.
    Moyano, Jose L.
    Sousa, Alejandro
    Fernandez, Jesus M.
    Gomez-Veiga, Francisco
    Unda, Miguel
    Carballido, Joaquin
    Carrero, Victor
    Fernandez-Aparicio, Tomas
    de Jalon, Angel Garcia
    Solsona, Eduardo
    Inman, Brant
    Palou, Joan
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (01): : 58 - 66
  • [2] Re: Hyperthermic Mitomycin C in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: Results of the HIVEC-1 Trial
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2023, 210 (06): : 929 - 930
  • [3] Defining intermediate-risk non-muscle-invasive bladder cancer
    S. Bruce Malkowicz
    Nature Reviews Urology, 2014, 11 : 430 - 432
  • [4] BLADDER CANCER Defining intermediate-risk non-muscle-invasive bladder cancer
    Malkowicz, S. Bruce
    NATURE REVIEWS UROLOGY, 2014, 11 (08) : 430 - 432
  • [5] Evaluation of the efficacy and safety of HIVEC intravesical thermochemotherapy with intermediate-risk and high-risk non-muscle-invasive bladder cancer
    Cimier, A.
    Thach, S.
    Lacroix, B.
    Mariat, C.
    PROGRES EN UROLOGIE, 2023, 33 (05): : 254 - 264
  • [6] The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
    Scilipoti, Pietro
    Slusarczyk, Aleksander
    de Angelis, Mario
    Soria, Francesco
    Pradere, Benjamin
    Krajewski, Wojciech
    D'Andrea, David
    Mari, Andrea
    Del Giudice, Francesco
    Pichler, Renate
    Subiela, Jose Daniel
    Afferi, Luca
    Albisinni, Simone
    Mertens, Laura
    Laukhtina, Ekaterina
    Mori, Keiichiro
    Radziszewski, Piotr
    Shariat, Shahrokh F.
    Necchi, Andrea
    Xylinas, Evanguelos
    Gontero, Paolo
    Roupret, Morgan
    Montorsi, Francesco
    Briganti, Alberto
    Moschini, Marco
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (06): : 1293 - 1302
  • [7] Treatment of intermediate-risk non-muscle-invasive bladder cancer (NMIBC)
    Hendricksen, Kees
    Witjes, J. Alfred
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (14) : 800 - 808
  • [8] Adjuvant therapy in intermediate-risk non-muscle-invasive bladder cancer
    Laukhtina, E.
    Moschini, M.
    Soria, F.
    Pradere, B.
    Yanagisawa, T.
    Kawada, T.
    Quhal, F.
    Von, Deimling M.
    Rajwa, P.
    Majdoub, M.
    Enikeev, D.
    Karakiewicz, P., I
    Robert, R. S.
    Babjuk, M.
    Shariat, S. F.
    EUROPEAN UROLOGY, 2023, 83
  • [9] Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer
    Laukhtina, Ekaterina
    Gontero, Paolo
    Babjuk, Marko
    Moschini, Marco
    Teoh, Jeremy Yuen-Chun
    Roupret, Morgan
    Trinh, Quoc-Dien
    Chlosta, Piotr
    Nyirady, Peter
    Abufaraj, Mohammad
    Soria, Francesco
    Klemm, Jakob
    Bekku, Kensuke
    Matsukawa, Akihiro
    Shariat, Shahrokh F.
    BJU INTERNATIONAL, 2024, 134 (04) : 644 - 651
  • [10] Bacillus Calmette-Guerin versus Mitomycin C for the Treatment of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: The Debate Continues
    Sylvester, Richard J.
    EUROPEAN UROLOGY, 2009, 56 (02) : 266 - 268
12345